Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma

2012293 citationsJournal Articlebronze Open Access

Authors

Sagar Lonial

Ravi Vij · New York University

Jean‐Luc Harousseau · Washington University in St. Louis

Thierry Façon · Multiple Myeloma Research Foundation

Philippe Moreau · Mount Sinai Hospital

Amitabha Mazumder · Hôpital Claude Huriez

Jonathan L. Kaufman · Mount Sinai Hospital

Abstract

The combination of elotuzumab, lenalidomide, and low-dose dexamethasone was generally well tolerated and showed encouraging response rates in patients with relapsed or refractory MM.

Topics & Keywords

Multiple Myeloma Research and Treatments Peptidase Inhibition and Analysis Protein Degradation and Inhibitors

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 30, Issue 16, pp. 1953-1959

DOI: 10.1200/jco.2011.37.2649

Field-Weighted Citation Impact: 23.20